Topics discussed at the Asembia Specialty Pharmacy Summit, held in May 2022 in Las Vegas, Nevada, touched on projections in specialty pharmacy and value-based payments, as well as experiences gained from the COVID-19 pandemic and evaluation of 340B drug pricing.
Below are some notable highlights from the event.
Adam Fein, PhD, of Drug Channels Institute, and Doug Long of IQVIA discussed how payers are restricting specialty pharmacy access for patients, and they noted that market shares held by specialty medicines are expected to exceed traditional medicines, particularly with the use of oncology biosimilars rising.
During the pandemic, value-based payment organizations were more successful than fee-for services organizations, and only time and feedback from patients and providers will tell if it will be sustainable for the future, said Jayson Slotnik, partner, Health Policy Strategies, Inc.
Scott Gottlieb, MD, and Adam Fein, PhD, spoke on how the United States and CDC were unprepared for the COVID outbreak. They also addressed the potential consequences of accelerated drug approval, such as with the drug aducanumab.
The 340B program has evolved and become more intricate since its inception, calling into question its ability to fulfill the original intention of helping underserved patients, explained Tim Paine, principal consultant at Blue Fin Group.